A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Completed · Phase 1
Conditions studied: Healthy, Renal Impairment
In brief
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic (PK) study). Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment (meaning the kidneys do not work properly) and to people who are in good health. The researchers believe that the total amount of enlicitide in a person's body measured during the 24 hours after a dose will be similar in people with severe renal impairment and in healthy people.
Key facts
- Study ID
- NCT06643377
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 27
- Starts
- 2024-11-22
- Expected to finish
- 2025-06-25
- Last updated by the study team
- 2025-07-23
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- The main inclusion criteria include but are not limited to the following:
- Body Mass Index (BMI) between 18 and 40 kg/m\^2, inclusive
- On a stable dose of statin therapy; no changes to dose or type of statin therapy for at least 2 months
You may not qualify if…
- The main exclusion criteria include but are not limited to the following:
- History or presence of renal artery stenosis
- Had a functioning renal transplant in the past 5 years and is taking transplant medication
- History of gastrointestinal (GI) disease which might affect food and drug absorption
- Panel A: Participants with Severe Renal Impairment:
- History of any illness, other than hypercholesterolemia and Renal Impairment
- Panel B: Healthy Participants:
- History of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases, other than hypercholesterolemia
Where it is running
- Velocity Clinical Research, New Smyrna Beach ( Site 0003) — Edgewater, Florida, United States
- Velocity Clinical Research, Hallandale Beach ( Site 0006) — Hallandale, Florida, United States
- Nature Coast Clinical Research - Inverness ( Site 0002) — Inverness, Florida, United States
- Jacksonville Center for Clinical Research ( Site 0004) — Jacksonville, Florida, United States
- Genesis Clinical Research, LLC ( Site 0001) — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.